The effectiveness and cost-effectiveness of an integrated osteoporosis care programme for postmenopausal women in Flanders: study protocol of a quasi-experimental controlled design

[1] Hernlund E(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-1384

[2] Svedbom A(2016)Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates Adv Ther 33 1374-121

[3] Ivergard M(2018)The relationship between protein quantity, BMD and fractures in older adults Ir J Med Sci 187 111-19

[4] Compston J(2005)Osteoporosis, inflammation and ageing Immun Ageing 2 14-191

[5] Cooper C(2017)Fragility fractures & their impact on older people Best Pract Res Clin Rheumatol 31 169-49

[6] Stenmark J(2009)Clinical subsequent fractures cluster in time after first fractures Ann Rheum Dis 68 99-3300

[7] McCloskey EV(2013)Osteoporosis in the European Union: a compendium of country-specific reports Arch Osteoporos 8 137-1146

[8] Jonsson B(2017)The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis J Bone Metab 24 37-1112

[9] Kanis JA(2017)Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis Osteoporos Int 28 3289-1061

[10] Goldshtein I(2017)Dietary inflammatory index, bone mineral density, and risk of fracture in postmenopausal women: results from the Women’s Health Initiative J Bone Miner Res 32 1136-911

[1] Hernlund E(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-1384

[2] Svedbom A(2016)Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates Adv Ther 33 1374-121

[3] Ivergard M(2018)The relationship between protein quantity, BMD and fractures in older adults Ir J Med Sci 187 111-19

[4] Compston J(2005)Osteoporosis, inflammation and ageing Immun Ageing 2 14-191

[5] Cooper C(2017)Fragility fractures & their impact on older people Best Pract Res Clin Rheumatol 31 169-49

[6] Stenmark J(2009)Clinical subsequent fractures cluster in time after first fractures Ann Rheum Dis 68 99-3300

[7] McCloskey EV(2013)Osteoporosis in the European Union: a compendium of country-specific reports Arch Osteoporos 8 137-1146

[8] Jonsson B(2017)The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis J Bone Metab 24 37-1112

[9] Kanis JA(2017)Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis Osteoporos Int 28 3289-1061

[10] Goldshtein I(2017)Dietary inflammatory index, bone mineral density, and risk of fracture in postmenopausal women: results from the Women’s Health Initiative J Bone Miner Res 32 1136-911